ROS1 and cancer: Oncogenic ALK and ROS1 fusion-targeted therapy using type I tyrosine-kinase inhibitors (TKIs), which bind to the ATP-binding cleft of kinases, is highly effective in lung adenocarcinoma (LADC)1,2; however, such cancers inevitably acquire resistance to targeted therapies, which severely limits the efficacy of cancer treatments.